CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR’s Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson’s Disease

  • Itanapraced blocks LRRK2 expression and LRRK2-mediated neurotoxicity
  • Itanapraced ready to advance to Phase 2 in Parkinson’s disease patients with and without genetic mutation

NEW YORK and SINGAPORE, Dec. 10, 2018 (GLOBE NEWSWIRE) — CERESPIR INCORPORATED a pharmaceutical company engaged in

Read More